Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Colorectal CancerAppendix CancerPeritoneal Carcinomatosis
Interventions
DRUG

Oxaliplatin

"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)"

Trial Locations (1)

01655

UMass Memorial Medical Center - University Campus, Worcester

All Listed Sponsors
lead

University of Massachusetts, Worcester

OTHER

NCT02833753 - Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI | Biotech Hunter | Biotech Hunter